2月19日 - ** Traws Pharma TRAW.O股价盘前下跌20.81%，报1.58美元
** 该公司称，美国 FDA 将其用于预防季节性流感的单片口服片剂 tivoxavir marboxil 的新药临床试验申请 (link) 搁置。
** 补充说，FDA 对申请药物的 "致突变性数据包 "表示担忧
** 还称提交申请是为了让政府的生物医学研究部门全面审查该药物是否可列入治疗禽流感的战略储备中
** 临床搁置不会直接影响美国以外正在进行和计划进行的研究；正在努力缓解临床开发计划中的问题 - TRAW
** TRAW 股价今年累计上涨 74.3%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.